130 related articles for article (PubMed ID: 19720812)
1. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.
Lavelle A; Sugrue R; Lawler G; Mulligan N; Kelleher B; Murphy DM; Gaine SP
Eur Respir J; 2009 Sep; 34(3):770-1. PubMed ID: 19720812
[No Abstract] [Full Text] [Related]
2. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
[No Abstract] [Full Text] [Related]
3. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Gibbs JS; Simonneau G
Eur Respir J; 2011 Feb; 37(2):475-6. PubMed ID: 21282816
[No Abstract] [Full Text] [Related]
4. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
[No Abstract] [Full Text] [Related]
5. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
Hoeper MM
Eur Respir J; 2009 Sep; 34(3):529-30. PubMed ID: 19720805
[No Abstract] [Full Text] [Related]
6. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.
Hoeper MM; Olsson KM; Schneider A; Golpon H
Eur Respir J; 2009 Jun; 33(6):1518-9. PubMed ID: 19483056
[No Abstract] [Full Text] [Related]
7. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Corris PA; Langleben D
Eur Respir J; 2010 Feb; 35(2):460-1; author reply 461. PubMed ID: 20123858
[No Abstract] [Full Text] [Related]
8. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.
Chin M; Levy RD; Yoshida EM; Byrne MF
Can Respir J; 2012; 19(1):e1-2. PubMed ID: 22332138
[TBL] [Abstract][Full Text] [Related]
9. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Owen K; Cross DM; Derzi M; Horsley E; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289
[TBL] [Abstract][Full Text] [Related]
10. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
11. Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan.
Prescrire Int; 2008 Jun; 17(95):108. PubMed ID: 18630348
[No Abstract] [Full Text] [Related]
12. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
13. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
Widlitz AC; Barst RJ; Horn EM
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
[TBL] [Abstract][Full Text] [Related]
14. Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Klein R; Hintz E; Staehler G
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22802555
[TBL] [Abstract][Full Text] [Related]
15. Sitaxsentan sodium for pulmonary hypertension.
MacIntyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
[TBL] [Abstract][Full Text] [Related]
16. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
17. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
Kähler CM; Graziadei I; Vogelsinger H; Desole S; Cima K; Vogel W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):248-52. PubMed ID: 21451953
[TBL] [Abstract][Full Text] [Related]
18. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
Pulido T; Sandoval J; Roquet I; Gutiérrez R; Rueda T; Peña H; Santos E; Miranda MT; Lupi E
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():14-8. PubMed ID: 19335742
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Cacoub P; Amoura Z; Langleben D
Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Langleben D
Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
